ImClone Erbitux Options: Add EU Colorectal Data, Refile As Head & Neck BLA
Executive Summary
ImClone may refile its Erbitux BLA in colorectal cancer using data from studies conducted by Merck KGaA, which holds the European rights to cetuximab
You may also be interested in...
Merck KGaA Erbitux Trial Designed With FDA Feedback On ImClone U.S. Trials
Merck KGaA's Erbitux Phase II trial in colorectal cancer will benefit from FDA feedback on ImClone's earlier U.S. trial designs, ImClone Chief Operating Officer Harlan Waksal said
Merck KGaA Erbitux Trial Designed With FDA Feedback On ImClone U.S. Trials
Merck KGaA's Erbitux Phase II trial in colorectal cancer will benefit from FDA feedback on ImClone's earlier U.S. trial designs, ImClone Chief Operating Officer Harlan Waksal said
Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions
Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies